Silver Book Fact

Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.

The Lasker Foundation. Exceptional Returns: The economic value of America’s investment in medical research. 2000; https://www.medscape.com/viewarticle/447944

Reference

Title
Exceptional Returns: The economic value of America’s investment in medical research
Publisher
Funding First
Publication Date
2000
Authors
The Lasker Foundation
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.